Matthias Mehling

This inventor holds 4 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Julius-Maximilians-Universitat Wurzburg. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Mehling. Retrieved from https://idiyas.com/inventor/matthias-mehling

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 4.8

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

4 out of 54

Julius-Maximilians-Universitat Wurzburg

patents

Years Active: 2022-2026

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12629418 - COMBINATION THERAPY USING INHIBITORS OF HUMAN GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15) AND IMMUNE CHECKPOINT BLOCKERS (2026-05-19),

2. 12473354 - GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS (2025-11-18),

3. 11464856 - Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers (2022-10-11),

4. 11262360 - GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers (2022-03-01),

Title: Matthias Mehling: Innovator in Cancer Treatment

Introduction

Matthias Mehling is a prominent inventor based in Basel, Switzerland. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of two patents, Mehling is dedicated to advancing medical science and improving patient outcomes.

Latest Patents

Mehling's latest patents focus on groundbreaking therapies for solid cancers. The first patent involves a combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) alongside immune checkpoint blockers. This invention aims to enhance treatment efficacy for patients suffering from various forms of cancer. The second patent addresses GDF-15 as a diagnostic marker to predict clinical outcomes for patients undergoing treatment with immune checkpoint blockers. This method provides valuable insights into treatment responses and survival probabilities for cancer patients.

Career Highlights

Matthias Mehling is affiliated with Julius-Maximilians-Universität Würzburg, where he conducts his research and develops his innovative therapies. His work has garnered attention in the medical community, contributing to advancements in cancer treatment methodologies.

Collaborations

Mehling collaborates with esteemed colleagues, including Jörg Wischhusen and Markus Haake. These partnerships enhance the research and development of effective cancer therapies, fostering a collaborative environment for innovation.

Conclusion

Matthias Mehling is a dedicated inventor whose work in cancer treatment is making a significant impact. His innovative patents and collaborations are paving the way for improved therapeutic strategies in oncology.

Profile summary based on public USPTO records.